In Vivo Investigation of Novel Nano-vesicles of Salbutamol Sulphate

Status Completed

Clinical Trial Summary

The relative bioavailability of different salbutamol sulphate inhaler formulations will be studied in healthy male subjects according to the ethical regulations of World Medical Association Declaration of Helsinki (1996) after the approval of the ethical committee, Faculty of Pharmacy, The British University in Egypt.

Clinical Trial Description

In this study, 20 healthy, non smoking, adult male volunteers (age: 30-45 years, weight: 65-80 kg) will carry out screening procedures which include instruction and practice with the placebo metered dose inhaler devices that will be used in the study. In addition, all subjects were fully informed in writing of the objectives and implications of the trial. No subject will be considered for the study if developed any symptoms of allergic disorders. Subjects will follow a normal diet and will not receive any other medications. Volunteers will be divided into two groups; each group contained 10 volunteers who will receive one formula of the selected formulae.

Each volunteer will inhale eight puffs (4 puffs at -5 min & 4 puffs at 0 min) which are equivalent to 0.8 mg of salbutamol sulphate . To inhale through metered dose inhalers, volunteers will be trained to exhale slowly to their residual volume (as far as comfortable), put the inhaler into their mouth and seal their lips round the mouth piece. Then they will be instructed to take a slow deep inspiration to their total lung capacity over approximately 5-10 seconds. At the end of each inhalation, they will hold their breath for 10 seconds and then breathe normally (Ball et al, 2002) . Three milliliters of blood will be withdrawn at 0, 0.5, 1, 2, 3, 4, 5 and 6 h after administration. The blood will be heparinized immediately and centrifuged at 3000 rpm for 10 minutes. The plasma samples will be stored at freeze temperature until analysis. Two different formulae will be compared during the first six hours following administration. The maximum plasma concentration (Cmax), the time required to reach maximum plasma concentration (Tmax) and the area under plasma concentration time curve (AUC) will be calculated using validated Excel software. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03059017
Study type	Interventional
Source	British University In Egypt
Contact
Status	Completed
Phase	Phase 1
Start date	February 5, 2017
Completion date	February 5, 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03572335` - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Recruiting	`NCT06088485` - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Terminated	`NCT03309358` - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis	Phase 1
Active, not recruiting	`NCT02504697` - DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Completed	`NCT01443845` - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)	Phase 4
Terminated	`NCT00524095` - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis	Phase 2
Completed	`NCT00210249` - Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Completed	`NCT00023114` - p450 Mediated Lung Toxicity	N/A
Recruiting	`NCT06056882` - Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
Completed	`NCT03994848` - Incentive Spirometry Prehabilitation Study	N/A
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Withdrawn	`NCT05100160` - Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)	Phase 3
Completed	`NCT03229473` - Fall Risk Assessment in COPD
Recruiting	`NCT04767074` - A Non-pharmacological Cough Control Therapy	N/A
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Completed	`NCT04996693` - On Dose Efficiency of Modern CT-scanners in Chest Scans	N/A
Recruiting	`NCT04996173` - Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)	N/A
Completed	`NCT04601545` - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method	N/A
Recruiting	`NCT03937583` - Screening for Cancer in Patients With Unprovoked VTE	Phase 4
Recruiting	`NCT02862418` - Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.